Author

Yunju Bae

Observed names: Bae, Yunju, Y Bae, Y. Bae, Y.M. Bae, YunJu Bae

Observed institution: Celltrion (South Korea)

ORCID: 0009-0002-3827-6742

Observed ORCID: 0009-0002-3827-6742

OpenAlex ID: A5023866431

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

2016 · Won Park, Dae Hyun Yoo, et al. · Annals of the Rheumatic Diseases · 229

PDF

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

2024 · Stephen B. Hanauer, Bruce E. Sands, et al. · Gastroenterology · 85

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

2023 · Kim A. Papp, Mark G. Lebwohl, et al. · BioDrugs · 32

PDF

DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).

2023 · J F Colombel, S B Hanauer, et al. · Journal of Crohn s and Colitis · 23

PDF

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

2023 · B E Sands, S B Hanauer, et al. · Journal of Crohn s and Colitis · 21

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

2024 · Josef S Smolen, Jakub Trefler, et al. · RMD Open · 13

PDF

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

2023 · Kyung-Sang Yu, Byungwook Kim, et al. · Expert Opinion on Investigational Drugs · 13

PDF

Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults

2023 · Miwa Haranaka, Takanori Tanaka, et al. · Immunotherapy · 10

Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe

2025 · Tomoko Hasunuma, Clive Grattan, et al. · Immunotherapy · 9

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)

2025 · Jean-Frederic Colombel, William J Sandborn, et al. · Journal of Crohn s and Colitis · 8

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males

2024 · Anhye Kim, Jang Hee Hong, et al. · Expert Opinion on Biological Therapy · 8

PDF

Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study

2025 · Clive Grattan, Yevgeniya Dytyatkovska, et al. · Clinical and Translational Allergy · 5

PDF

Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.

2017 · Won Seog Kim, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 5

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

2024 · Kyung-Sang Yu, Hyunwook Ryu, et al. · Expert Opinion on Biological Therapy · 4

1028 Subcutaneous Infliximab (ct-p13) as Maintenance Therapy for Crohn's Disease: a Phase 3, Randomized, Placebo-controlled Study (liberty-cd).

2023 · Stephen B. Hanauer, Jean Frederic Colombel, et al. · Gastroenterology · 4

PDF

A Double‐blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Ct‐p10 to Rituximab in Combination With Cvp in Patients With Advanced‐stage Follicular Lymphoma

2017 · C. Buske, W. Kim, et al. · Hematological Oncology · 3

PDF

AB0433 Meta-Analysis of the Safety Data Between Infliximab Biosimilar (CT-P13) and Innovator Infliximab in Rheumatoid Arthritis and Ankylosing Spondylitis

2015 · W. Park, D.H. Yoo, et al. · Annals of the Rheumatic Diseases · 3

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

2024 · J F Colombel, S B Hanauer, et al. · Journal of Crohn s and Colitis · 2

PDF

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

2024 · B E Sands, S B Hanauer, et al. · Journal of Crohn s and Colitis · 2

PDF

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

2018 · Michinori Ogura, Juan Manuel Sancho, et al. · Blood · 2

Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease

2026 · Diane R Mould, Maximillian Kutschera, et al. · World Journal of Gastroenterology · 1

PDF

Two-year Results of Subcutaneous Infliximab (ct-p13 Sc) Dose Escalation Therapy - From Liberty-cd and Liberty-uc

2025 · Stephen B. Hanauer, Silvio Danese, et al. · Gastroenterology · 1

PDF

Ab0027 Pharmacokinetics and Safety of Ct-p47, a Proposed Tocilizumab Biosimilar, in Comparison With Intravenous Eu-approved Tocilizumab and Us-licensed Tocilizumab; a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Japanese Subjects

2024 · M. Haranaka, T. Eto, et al. · Annals of the Rheumatic Diseases · 1

Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

2023 · William J. Sandborn, Bruce E. Sands, et al. · Gastroenterology · 1

PDF

Ab0198 Efficacy and Safety After Transition From Reference Adalimumab to Ct-p17 (adalimumab Biosimilar: 100 Mg/ml) in Comparison With the Maintained Treatment (ct-p17 or Reference Adalimumab) in Patients With Moderate-to-severe Active Rheumatoid Arthritis: 1-year Result

2021 · D. Furst, E. Keystone, et al. · Annals of the Rheumatic Diseases · 1

PDF

Works count: 32

Citation count: 486

H-index: 9

I10-index: 8